Trastuzumab rezetecan with or without everolimus for advanced triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new combination treatment for a specific type of advanced triple-negative breast cancer. It compares the study drug given alone versus with another medicine, to see which is more effective in slowing the cancer down.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old
- You have a specific type of advanced triple-negative breast cancer (LAR subtype), which has spread or cannot be removed by surgery
- You have had up to 2 prior treatments for advanced disease
- You have not had certain cardiac or other serious medical conditions
- You are able to swallow tablets
- You are not pregnant or planning to become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called Trastuzumab Rezetecan, either alone or combined with Bevacizumab, for people with a specific type of advanced triple-negative breast cancer that has been treated with up to two prior therapies. The goal is to see if these drugs can shrink tumors or slow cancer growth.
This trial tests a stronger follow-up treatment (intensification) for women with a specific type of triple-negative breast cancer that has high androgen receptors. It is for those who did not have a complete response to chemotherapy before surgery and do not have a BRCA1/2 mutation.
This trial tests a combination of two drugs (serplulimab and trastuzumab rezetecan) given before surgery to shrink tumors in people with early-stage triple-negative breast cancer. The goal is to see if this treatment helps remove more cancer cells before the main surgery.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
This trial tests a combination of new drugs (HRS-8080, SHR-A2009, or others) for people with advanced breast cancer that has stopped responding to previous treatments. The goal is to see if these combinations can shrink tumors or slow the cancer's growth.
This Phase 2 trial tests whether adding everolimus to standard first-line hormone (endocrine) therapy can better control a certain type of advanced breast cancer. It is designed for people whose tumor matches a specific “SNF1 subtype.”
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.